TP53 and cancer: Through analysis of recently published, prospective clinical sequencing data representing diverse cancer types [1], mutations (missense, truncating, or in frame) were found to be the most frequent TP53 alterations (n = 4514/4618; 97.7%), while copy number changes (n = 80/4618; 1.7%), defined as a fusion, amplification, or deletion event (Fig. 1A, left) were found to be less common [1, 8, 18].